Austar Lifesciences (HKG:6118) Full Year 2024 Results
Key Financial Results
- Revenue: CN¥1.50b (down 15% from FY 2023).
- Net income: CN¥16.1m (up from CN¥32.6m loss in FY 2023).
- Profit margin: 1.1% (up from net loss in FY 2023).
- EPS: CN¥0.031 (up from CN¥0.064 loss in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
The primary driver behind last 12 months revenue was the Integrated Process and Packaging Systems segment contributing a total revenue of CN¥821.3m (55% of total revenue). Notably, cost of sales worth CN¥1.20b amounted to 80% of total revenue thereby underscoring the impact on earnings. The largest operating expense was Sales & Marketing costs, amounting to CN¥131.9m (46% of total expenses). Explore how 6118's revenue and expenses shape its earnings.
Austar Lifesciences shares are down 2.5% from a week ago.
Risk Analysis
It's necessary to consider the ever-present spectre of investment risk. We've identified 3 warning signs with Austar Lifesciences (at least 1 which is a bit concerning), and understanding these should be part of your investment process.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.